Hello_老虎社区_美港股上老虎

2021-06-29

Hello

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":159959650,"tweetId":"159959650","gmtCreate":1624937590270,"gmtModify":1631890986807,"author":{"id":3584285120687544,"idStr":"3584285120687544","authorId":3584285120687544,"authorIdStr":"3584285120687544","name":"CTitan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Hello</body></html>","htmlText":"<html><head></head><body>Hello</body></html>","text":"Hello","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/159959650","repostId":1124906464,"repostType":4,"repost":{"id":"1124906464","kind":"news","pubTimestamp":1624936236,"share":"https://www.laohu8.com/m/news/1124906464?lang=&edition=full","pubTime":"2021-06-29 11:10","market":"us","language":"en","title":"CVRx Pursues $100 Million U.S. IPO Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1124906464","media":"seekingalpha","summary":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commerc","content":"Summary\n<ul>\n <li>CVRx has filed to raise $100 million in a U.S. IPO of its common stock.</li>\n <li>The firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.</li>\n <li>CVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.</li>\n <li>Looking for more investing ideas like this one? Get them exclusively at IPO Edge.</li>\n</ul>\nCVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.\nThe firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.\nCVRX was negatively affected by the COVID-19 pandemic but has rebounded.\nHowever, the IPO appears pricey, so I'll watch it from the sidelines.\nCompany and Technology\nMinneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.\nManagement is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.\nCVRx has received at least $330 million in equity investment from investors including Johnson &amp; Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.\nCustomer Acquisition and Market\nThe firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.\nThe firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.\nSelling, G&amp;A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:\n<table>\n <tbody>\n <tr>\n <td>Selling, G&amp;A</td>\n <td>Expenses vs. Revenue</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Percentage</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>155.9%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>160.5%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>97.6%</td>\n </tr>\n </tbody>\n</table>\n(Source)\nThe Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:\n<table>\n <tbody>\n <tr>\n <td>Selling, G&amp;A</td>\n <td>Efficiency Rate</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Multiple</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>0.3</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>0.0</td>\n </tr>\n </tbody>\n</table>\n(Source)\nAccording to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.\nThis represents a forecast CAGR of 13.1% from 2016 to 2022.\nThe main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.\nAlso, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.\nFinancial Performance\nCVRx’s recent financial results can be summarized as follows:\n<ul>\n <li>Rebounding topline revenue growth</li>\n <li>Increasing gross profit but uneven gross margin</li>\n <li>Growing operating losses</li>\n <li>Increasing cash used in operations</li>\n</ul>\nBelow are relevant financial results derived from the firm’s registration statement:\n<table>\n <tbody>\n <tr>\n <td>Total Revenue</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Total Revenue</td>\n <td>% Variance vs. Prior</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>$ 2,860,000</td>\n <td>66.5%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 6,053,000</td>\n <td>-3.3%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ 6,257,000</td>\n </tr>\n <tr>\n <td>Gross Profit (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Gross Profit (Loss)</td>\n <td>% Variance vs. Prior</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>$ 1,993,000</td>\n <td>55.0%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ 4,613,000</td>\n <td>0.9%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ 4,574,000</td>\n </tr>\n <tr>\n <td>Gross Margin</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Gross Margin</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>69.69%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>76.21%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>73.10%</td>\n </tr>\n <tr>\n <td>Operating Profit (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Operating Profit (Loss)</td>\n <td>Operating Margin</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>$ (4,217,000)</td>\n <td>-147.4%</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ (11,514,000)</td>\n <td>-190.2%</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (10,194,000)</td>\n <td>-162.9%</td>\n </tr>\n <tr>\n <td>Net Income (Loss)</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Net Income (Loss)</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>$ (8,627,000)</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ (14,109,000)</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (14,633,000)</td>\n </tr>\n <tr>\n <td>Cash Flow From Operations</td>\n </tr>\n <tr>\n <td>Period</td>\n <td>Cash Flow From Operations</td>\n </tr>\n <tr>\n <td>Three Mos. Ended March 31, 2021</td>\n <td>$ (5,038,000)</td>\n </tr>\n <tr>\n <td>2020</td>\n <td>$ (16,096,000)</td>\n </tr>\n <tr>\n <td>2019</td>\n <td>$ (12,785,000)</td>\n </tr>\n <tr>\n <td>(Glossary Of Terms)</td>\n </tr>\n </tbody>\n</table>\n(Source)\nAs of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.\nFree cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).\nIPO Details\nCVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nManagement says it will use the net proceeds from the IPO as follows:\n<blockquote>\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n</blockquote>\nManagement’s presentation of the company roadshow isavailable here.\nListed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n<table>\n <tbody>\n <tr>\n <td>Measure [TTM]</td>\n <td>Amount</td>\n </tr>\n <tr>\n <td>Market Capitalization at IPO</td>\n <td>$296,717,728</td>\n </tr>\n <tr>\n <td>Enterprise Value</td>\n <td>$170,592,728</td>\n </tr>\n <tr>\n <td>Price / Sales</td>\n <td>41.24</td>\n </tr>\n <tr>\n <td>EV / Revenue</td>\n <td>23.71</td>\n </tr>\n <tr>\n <td>EV / EBITDA</td>\n <td>-13.70</td>\n </tr>\n <tr>\n <td>Earnings Per Share</td>\n <td>-$0.97</td>\n </tr>\n <tr>\n <td>Float To Outstanding Shares Ratio</td>\n <td>33.70%</td>\n </tr>\n <tr>\n <td>Proposed IPO Midpoint Price per Share</td>\n <td>$16.00</td>\n </tr>\n <tr>\n <td>Net Free Cash Flow</td>\n <td>-$16,946,000</td>\n </tr>\n <tr>\n <td>Free Cash Flow Yield Per Share</td>\n <td>-5.71%</td>\n </tr>\n <tr>\n <td>Revenue Growth Rate</td>\n <td>66.47%</td>\n </tr>\n <tr>\n <td>(Glossary Of Terms)</td>\n </tr>\n </tbody>\n</table>\n(Source)\nCommentary\nCVRx is seeking public investment capital for its continued commercialization efforts.\nThe company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.\nRevenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.\nFree cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).\nSelling, G&amp;A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&amp;A efficiency rate has since increased to 0.3x in Q1 2021.\nThe market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.\nAs for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.\nWhile CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.\nExpected IPO Pricing Date: June 29, 2021","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRx Pursues $100 Million U.S. IPO Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRx Pursues $100 Million U.S. IPO Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-29 11:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan>seekingalpha</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nSummary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has ...\n\n<a href=\"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVRX":"CVRx, Inc."},"source_url":"https://seekingalpha.com/article/4436978-cvrx-pursues-100-million-us-ipo-plan","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1124906464","content_text":"Summary\n\nCVRx has filed to raise $100 million in a U.S. IPO of its common stock.\nThe firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.\nCVRX has rebounded from the negative effects of the COVID-19 pandemic but the IPO appears pricey, so I'll watch it from the sidelines.\nLooking for more investing ideas like this one? Get them exclusively at IPO Edge.\n\nCVRx (CVRX) has filed to raise $100 million in an IPO of its common stock, according to an S-1/Aregistration statement.\nThe firm is commercializing a neurostimulation device to treat patients with systolic Heart failure symptoms.\nCVRX was negatively affected by the COVID-19 pandemic but has rebounded.\nHowever, the IPO appears pricey, so I'll watch it from the sidelines.\nCompany and Technology\nMinneapolis, Minnesota-based CVRx was founded to develop its BAROSTIM device that sends persistent electrical pulses tobaroreceptors inside the wall of the carotid artery as a signal to the brain to modulate cardiovascular function.\nManagement is headed by president and CEO NadimYaredwho has been with the firm since 2006 and was previously vice president and general manager of Medtronic Navigation.\nCVRx has received at least $330 million in equity investment from investors including Johnson & Johnson, New Enterprise Associates, Cooperative Glide Healthcare, Vensana Capital, Action Potential Venture Capital and Treo Ventures.\nCustomer Acquisition and Market\nThe firm sells its BAROSTIM NEO to hospitals through its direct sales organizations in the U.S. and Germany and through distributors in other European countries.\nThe firm saw a reduction in demand in 2020 due to the restriction of hospital access to patients with relevant conditions.\nSelling, G&A expenses as a percentage of total revenue have risen as revenues have fluctuated, as the figures below indicate:\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nThree Mos. Ended March 31, 2021\n155.9%\n\n\n2020\n160.5%\n\n\n2019\n97.6%\n\n\n\n(Source)\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.3x in the most recent reporting period, as shown in the table below:\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nThree Mos. Ended March 31, 2021\n0.3\n\n\n2020\n0.0\n\n\n\n(Source)\nAccording to a 2016 marketresearch reportby Allied Market Research, the global market for neuromodulation is expected to reach $11.7 billion by 2022.\nThis represents a forecast CAGR of 13.1% from 2016 to 2022.\nThe main drivers for this expected growth are a growing geriatric population and a resulting increase in neurological disorders.\nAlso, an increase in Alzheimer's and Parkinson's disease conditions also will likely add to demand.\nFinancial Performance\nCVRx’s recent financial results can be summarized as follows:\n\nRebounding topline revenue growth\nIncreasing gross profit but uneven gross margin\nGrowing operating losses\nIncreasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\n\n\nTotal Revenue\n\n\nPeriod\nTotal Revenue\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 2,860,000\n66.5%\n\n\n2020\n$ 6,053,000\n-3.3%\n\n\n2019\n$ 6,257,000\n\n\nGross Profit (Loss)\n\n\nPeriod\nGross Profit (Loss)\n% Variance vs. Prior\n\n\nThree Mos. Ended March 31, 2021\n$ 1,993,000\n55.0%\n\n\n2020\n$ 4,613,000\n0.9%\n\n\n2019\n$ 4,574,000\n\n\nGross Margin\n\n\nPeriod\nGross Margin\n\n\nThree Mos. Ended March 31, 2021\n69.69%\n\n\n2020\n76.21%\n\n\n2019\n73.10%\n\n\nOperating Profit (Loss)\n\n\nPeriod\nOperating Profit (Loss)\nOperating Margin\n\n\nThree Mos. Ended March 31, 2021\n$ (4,217,000)\n-147.4%\n\n\n2020\n$ (11,514,000)\n-190.2%\n\n\n2019\n$ (10,194,000)\n-162.9%\n\n\nNet Income (Loss)\n\n\nPeriod\nNet Income (Loss)\n\n\nThree Mos. Ended March 31, 2021\n$ (8,627,000)\n\n\n2020\n$ (14,109,000)\n\n\n2019\n$ (14,633,000)\n\n\nCash Flow From Operations\n\n\nPeriod\nCash Flow From Operations\n\n\nThree Mos. Ended March 31, 2021\n$ (5,038,000)\n\n\n2020\n$ (16,096,000)\n\n\n2019\n$ (12,785,000)\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nAs of March 31, 2021, CVRx had $54 million in cash and $32.1 million in total liabilities.\nFree cash flow during the twelve months ended March 31, 2021, was negative ($16.9 million).\nIPO Details\nCVRx intends to raise $100 million in gross proceeds from an IPO of its common stock, offering 6.25 million shares at a proposed midpoint price of $16.00 per share.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO, the company’s enterprise value at IPO would approximate $170.6 million, excluding the effects of underwriter over-allotment options.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 33.7%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nManagement says it will use the net proceeds from the IPO as follows:\n\n Approximately $75.0 million to continue funding the expansion of our direct sales force and commercial organization related to BAROSTIM NEO in the U.S.;Approximately $12.0 million to fund research and development activities related to BAROSTIM Therapy; andThe remainder for working capital and general corporate purposes. (Source)\n\nManagement’s presentation of the company roadshow isavailable here.\nListed bookrunners of the IPO are JPMorgan, Piper Sandler, William Blair and Canaccord Genuity.\nValuation Metrics\nBelow is a table of relevant capitalization and valuation figures for the company:\n\n\n\nMeasure [TTM]\nAmount\n\n\nMarket Capitalization at IPO\n$296,717,728\n\n\nEnterprise Value\n$170,592,728\n\n\nPrice / Sales\n41.24\n\n\nEV / Revenue\n23.71\n\n\nEV / EBITDA\n-13.70\n\n\nEarnings Per Share\n-$0.97\n\n\nFloat To Outstanding Shares Ratio\n33.70%\n\n\nProposed IPO Midpoint Price per Share\n$16.00\n\n\nNet Free Cash Flow\n-$16,946,000\n\n\nFree Cash Flow Yield Per Share\n-5.71%\n\n\nRevenue Growth Rate\n66.47%\n\n\n(Glossary Of Terms)\n\n\n\n(Source)\nCommentary\nCVRx is seeking public investment capital for its continued commercialization efforts.\nThe company’s financials show the negative effects of the COVID-19 pandemic on its revenue trajectory in 2020 as hospitals cut back on patient access to its products.\nRevenue growth and gross profit appears to have rebounded significantly in Q1 2021, although some of this growth may represent pent-up demand and may not necessarily be representative of a more sustainable growth path going forward.\nFree cash flow for the twelve months ended March 31, 2021, was negative ($16.9 million).\nSelling, G&A expenses as a percentage of total revenue grew sharply in 2020 as revenue growth stalled during that period; its Selling, G&A efficiency rate has since increased to 0.3x in Q1 2021.\nThe market opportunity for providing neuromodulation approaches to heart failure are significant and the firm appears well positioned to take advantage of a growing elderly patient population as the U.S. geriatric population grows substantially over the coming years.\nJPMorgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 36.8% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the reimbursement process and penetration, both within the U.S. and internationally, which varies greatly from region to region.\nAs for valuation, management is asking investors to pay an EV/revenue multiple of 23.7x, which appears to be priced for perfection, especially so soon after its sales were negatively affected by the pandemic.\nWhile CVRx will likely have an impressive growth year in 2021, paying nearly 24x trailing EV/revenue and 41x on a price/sales multiple is excessive in my view.\nExpected IPO Pricing Date: June 29, 2021","news_type":1},"isVote":1,"tweetType":1,"viewCount":186,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/159959650"}